Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | PARP1 | P09874 | 2/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | APEX1 | P27695 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17849875 | 1.00 | ALDH1A1 (0.42) | ALDH1A1KDM4EPARP1CRBNMEN1 | |
| SCHEMBL18766568 | 0.95 | ALDH1A1 (0.47) | ALDH1A1KDM4EPARP1CRBNMEN1 | |
| SCHEMBL17849862 | 0.95 | ALDH1A1 (0.47) | ALDH1A1KDM4EPARP1CRBNMEN1 | |
| SCHEMBL17849874 | 0.78 | ALDH1A1 (0.44) | ALDH1A1KDM4EPARP1CRBNMEN1 | |
| SCHEMBL12108606 | 0.73 | KDM4E (0.39) | ALDH1A1KDM4EPARP1CRBNMEN1 | |
| SCHEMBL12108631 | 0.73 | KDM4E (0.39) | ALDH1A1KDM4EPARP1CRBNMEN1 | |
| SCHEMBL5579426 | 0.73 | ALDH1A1 (0.53) | ALDH1A1KDM4ECRBNMEN1KMT2A | |
| SCHEMBL27123348 | 0.73 | ALDH1A1 (0.53) | ALDH1A1KDM4ECRBNMEN1KMT2A | |
| SCHEMBL12110918 | 0.72 | KDM4E (0.38) | ALDH1A1KDM4EPARP1CRBNMEN1 | |
| SCHEMBL12110798 | 0.72 | KDM4E (0.38) | ALDH1A1KDM4EPARP1CRBNMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2017-04-20 | — | — | US | disclosed |
| US-9371283-B2 | Polycyclic tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2016-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170107179-A1 | Polycyclic Tetracycline Compounds | TET1, TUBA1C, TUBB | ALDH1A1 3821/4885KDM4E 2649/4885PARP1 2553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.